JOP20200190A1 - مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat) - Google Patents

مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat)

Info

Publication number
JOP20200190A1
JOP20200190A1 JOP/2020/0190A JOP20200190A JOP20200190A1 JO P20200190 A1 JOP20200190 A1 JO P20200190A1 JO P20200190 A JOP20200190 A JO P20200190A JO P20200190 A1 JOP20200190 A1 JO P20200190A1
Authority
JO
Jordan
Prior art keywords
pyridin
methyl
ghrelin
goat
inhibitors
Prior art date
Application number
JOP/2020/0190A
Other languages
English (en)
Inventor
Thomas Trieselmann
Christoph Hoenke
Viktor Vintonyak
Cédrickx Godbout
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20200190A1 publication Critical patent/JOP20200190A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بالصيغة العامة I، حيث تكون المجموعات R1 وR2 كما تم تعريفها في عنصر الحماية 1، حيث يكون لها خواص صيدلانية مفيدة، بالتحديد ترتبط بجريلين O- أسيل ترانسفيراز (GOAT) وتعدّل نشاطه. تكون المركبات مناسبة لمعالجة والوقاية من أمراض حيث يمكن أن تتأثر بهذا المستقبل، مثل الأمراض الأيضية، بالتحديد السمنة.
JOP/2020/0190A 2018-02-02 2019-01-28 مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat) JOP20200190A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154824 2018-02-02
PCT/EP2019/051989 WO2019149657A1 (en) 2018-02-02 2019-01-28 Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors

Publications (1)

Publication Number Publication Date
JOP20200190A1 true JOP20200190A1 (ar) 2020-07-29

Family

ID=61157050

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0190A JOP20200190A1 (ar) 2018-02-02 2019-01-28 مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat)

Country Status (21)

Country Link
US (1) US11254688B2 (ar)
EP (1) EP3746451B1 (ar)
JP (1) JP7015396B2 (ar)
KR (1) KR20200116978A (ar)
CN (1) CN111655700B (ar)
AU (1) AU2019215707A1 (ar)
BR (1) BR112020013082A2 (ar)
CA (1) CA3087826A1 (ar)
CL (1) CL2020001907A1 (ar)
CO (1) CO2020009299A2 (ar)
CR (1) CR20200332A (ar)
EA (1) EA202091805A1 (ar)
EC (1) ECSP20050785A (ar)
IL (1) IL276136A (ar)
JO (1) JOP20200190A1 (ar)
MA (1) MA53075A (ar)
MX (1) MX2020008053A (ar)
PE (1) PE20210174A1 (ar)
PH (1) PH12020551168A1 (ar)
SG (1) SG11202006125VA (ar)
WO (1) WO2019149657A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874587T3 (es) 2016-08-05 2021-11-05 Boehringer Ingelheim Int Derivados de oxadiazolopiridina para su uso como inhibidores de la grelina O-aciltransferasa (GOAT)
WO2019149658A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CA3087925A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
EP4153600A1 (en) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法
WO2023114472A1 (en) * 2021-12-16 2023-06-22 Icahn School Of Medicine At Mount Sinai Heterocyclic compounds as 5ht2a biased agonists
CN114426516B (zh) * 2022-02-16 2022-11-04 安徽有吉医药科技有限公司 一种2-氨基-3-溴吡啶的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082383A1 (en) 2003-03-17 2004-09-30 Basf Aktiengesellschaft Use of triazolopyrimidines for combating nematode diseases of plants
JP2009542809A (ja) * 2006-07-12 2009-12-03 メルク エンド カムパニー インコーポレーテッド グレリン受容体アンタゴニストとしての置換ピラゾール
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
IL309201A (en) 2007-04-11 2024-02-01 Canbas Co Ltd Compounds with anticancer activity
JP2010527951A (ja) 2007-05-24 2010-08-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
FR2933989B1 (fr) 2008-07-16 2013-03-08 Commissariat Energie Atomique Procede de purification de microorganismes presents dans des echantillons liquides
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
CA2747109A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
EA020497B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
US20110078154A1 (en) 2009-09-28 2011-03-31 Accenture Global Services Gmbh Recruitment screening tool
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
EP2793931A2 (en) 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
ES2640258T3 (es) * 2012-02-24 2017-11-02 Takeda Pharmaceutical Company Limited Compuesto anular aromático como inhibidor de grelina o-aciltransferasa
US9492448B2 (en) 2012-06-20 2016-11-15 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
US20170275249A1 (en) * 2014-09-17 2017-09-28 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
JP6615896B2 (ja) * 2015-01-30 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロン合成酵素阻害剤
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MX2018004947A (es) 2015-10-22 2018-11-09 Cavion Inc Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
ES2874587T3 (es) * 2016-08-05 2021-11-05 Boehringer Ingelheim Int Derivados de oxadiazolopiridina para su uso como inhibidores de la grelina O-aciltransferasa (GOAT)
SG10202101247QA (en) * 2016-08-11 2021-03-30 Cellix Bio Private Ltd Compositions and methods for the treatment of irritable bowel syndrome
WO2018044663A1 (en) 2016-08-29 2018-03-08 Merck Sharp & Dohme Corp. Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020008116A (es) 2018-02-02 2020-09-25 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
CA3087925A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Also Published As

Publication number Publication date
CR20200332A (es) 2020-09-03
US11254688B2 (en) 2022-02-22
PH12020551168A1 (en) 2021-05-31
JP2021512113A (ja) 2021-05-13
KR20200116978A (ko) 2020-10-13
JP7015396B2 (ja) 2022-02-15
CN111655700A (zh) 2020-09-11
CA3087826A1 (en) 2019-08-08
ECSP20050785A (es) 2020-09-30
CL2020001907A1 (es) 2020-10-30
PE20210174A1 (es) 2021-01-29
MX2020008053A (es) 2020-09-07
IL276136A (en) 2020-09-30
MA53075A (fr) 2021-05-12
EA202091805A1 (ru) 2020-12-16
AU2019215707A1 (en) 2020-07-09
SG11202006125VA (en) 2020-07-29
CN111655700B (zh) 2023-07-18
BR112020013082A2 (pt) 2020-12-01
US20210053985A1 (en) 2021-02-25
WO2019149657A1 (en) 2019-08-08
EP3746451A1 (en) 2020-12-09
EP3746451B1 (en) 2023-07-12
CO2020009299A2 (es) 2020-08-21

Similar Documents

Publication Publication Date Title
PH12020551168A1 (en) Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
PH12020551170A1 (en) Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
PH12019500254A1 (en) Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
PH12020551169A1 (en) Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2021005311A (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock).
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
PH12020551208A1 (en) Compounds for the treatment of kinase-dependent disorders
MX2020001103A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
TN2017000009A1 (en) Spirocycloheptanes as inhibitors of rock.
MX2020005515A (es) Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
MX2020006181A (es) Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5.
MX2020006168A (es) Compuestos de 4-azaindol.
MX369159B (es) Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer.
MX2020005462A (es) Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
MX2020006014A (es) Compuestos de diazaindol.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2012001999A (es) Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2.
MX2023000198A (es) Inhibidores de atr y usos de estos.
MX2020005471A (es) Compuestos para el tratamiento de trastornos neuromusculares.
EA201991509A1 (ru) Аминозамещенные гетероциклические соединения в качестве ингибиторов ehmt2 и способы их применения
MX2020005398A (es) Compuestos para el tratamiento de trastornos neuromusculares.